Navigation Links
Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
Date:12/28/2012

FRIDAY, Dec. 28 (HealthDay News) For breast cancer patients prescribed tamoxifen to treat their disease, genetic traits affecting an enzyme in the liver are major players in determining the impact of the hormone therapy, new research suggests.

There's been debate in the scientific world for years over the role of genetic differences in the enzyme, known as CYP2D6. An estimated 5 percent to 7 percent of European and North American women have a trait that prevents the enzyme from working properly.

"Our findings confirm that, in early breast cancer treated with tamoxifen, genetic alterations in CYP2D6 lead to a higher likelihood of recurrence and death," Dr. Matthew Goetz, a Mayo Clinic oncologist and lead author of the study that reported the findings, said in a Mayo Clinic news release.

The researchers tracked two groups of women: postmenopausal women with primary estrogen receptor-positive breast cancer who received tamoxifen for five years, and those took got the drug for two years followed by another drug, anastrozole, for three years.

Among those who took tamoxifen for five years, those whose genetic makeup prevented the enzyme from being able to process things were 2.5 times more likely to die or have their cancer return than those whose enzymes worked normally, the investigators found.

However, genetic traits involving the enzyme didn't seem to influence the fates of the women who switched to anastrozole, an aromatase inhibitor, after two years of tamoxifen, the study found.

"Switching from tamoxifen to an aromatase inhibitor may be one reason for the discrepant studies surrounding CYP2D6 and tamoxifen -- as information about whether a patient took an aromatase inhibitor after tamoxifen was not available in most of the prior studies," senior author Dr. James Ingle, of the Mayo Clinic, said in the news release.

Goezt thinks the study findings confirm that women should switch from tamoxifen to an aromatase inhibitor, or avoid tamoxifen altogether, if tests show they have the genetic trait that limits the metabolizing process.

The study was released online in advance of publication in an upcoming print issue of the journal Clinical Cancer Research.

More information

For more about breast cancer, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCE: Mayo Clinic, news release, Dec. 26, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genes Linked to Autism Seem to Have Strong Tendency to Mutate
2. Scientists Now See 200 Genes Linked to Crohns Disease
3. Genes May Influence Effectiveness of Anti-Smoking Policies
4. Ethiopians and Tibetans thrive in thin air using similar physiology, but different genes
5. Valuable tool for predicting pain genes in people
6. A relationship between cancer genes and the reprogramming gene SOX2 discovered
7. Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
8. 1000 genomes study is guidebook to how genes vary
9. New findings on mens genes could alter interpretation of PSA test
10. Scientists step up hunt for bacterial genes tied to Lyme disease
11. Scientists to study the role genes play in treating TB
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... ... Mediaplanet is proud to announce the launch of its ... therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage their ... the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This is ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016  PipelineRx, a leading medication management technology ... demonstrations of its SaaS-based telepharmacy platform, PowerGridRx™ ... 2016 Midyear Clinical Meeting and Exhibition, December 5-7 ... nearly 300 hospital clients nationally, the Company is ... to dramatically improve pharmacy operations, enhance patient safety, ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and ... financial guidance for 2017 and provide updated financial guidance ... also conduct a conference call on that day with ... company,s financial guidance. The conference call will ... general public can access a live webcast of the ...
(Date:12/2/2016)... MARLBOROUGH, Mass. , Dec. 2, 2016 ... announced a definitive agreement to acquire certain manufacturing assets ... NVCN ) (TSX: NVC) advanced biological tissue business, as ... a total of $75 million in cash. The Neovasc ... heart valves, including the Boston Scientific Lotus™ Valve System. ...
Breaking Medicine Technology: